Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK085618-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
unable to complete due to lack of funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will investigate the effect of wearing a small warming patch, the InsuPatch, at the site of the continuous glucose monitor (CGM), also called a sensor. Specifically, we will be looking to see if using the InsuPatch (IP) improves the accuracy of the continuous glucose monitor.
Hypotheses:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sensor alone | Active Comparator | Glucose sensor site will not have Insupatch |
|
| Sensor with Insupatch | Experimental | Glucose sensor site with Insupatch |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Insupatch | Device | Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use. | Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use, comparing sensor glucose readings and signal data to serum Yellow Springs Instrument (YSI) glucose measurements, with each subject acting as his or her own control. | 4 hours after lunch, 8 hours after breakfast |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol
The presence of any of the following diseases:
a. Current use of systemic corticosteroids (within the last week) b. Other major illness that in the judgment of the investigator might interfere with the completion of the protocol i. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
Current or past use of a continuous glucose sensor is not an exclusion criterion.
Active skin condition that would affect sensor placement
Use of acetaminophen or Vitamin C supplement within the last 7 days
Subject is deemed by the Investigator to be unwilling or unable to follow the protocol;
Pregnancy A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Camille Michaud, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale University School of Medicine | New Haven | Connecticut | 06520 | United States |
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Continuous glucose sensor | Device | Glucose sensor inserted without warming patch |
|
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |